Browse through our press and news section by category:

04.02.2015, Paris

Ready when you are

SCHOTT to display ready-to-use packaging and solutions for sensitive formulations at Pharmapack 2015
Paris, February 4, 2015 – Ready-to-use packaging saves pharmaceutical companies time and money. And SCHOTT has just the right solutions to support the industry’s ready-to-use filling strategies with pre-sterilized packaging. The company invites the pharmaceutical industry to find out more about its range of ready-to-use syringes, vials and cartridges at the Pharmapack 2015 trade show in Paris (February 11 – 12). At booth 702 SCHOTT will also be showcasing its latest solutions for sensitive formulations – SCHOTT Vials Delamination Controlled and syrSCHOTT iQ® InJentle prefillable glass syringes.

The company will be revealing new formats of SCHOTT Vials Delamination Controlled, which will be available soon. SCHOTT Vials DC represent an improved glass packaging designed to lower the risk of delamination. Thanks to high-quality FIOLAX® glass with excellent chemical properties combined with an improved manufacturing process these vials provide a more homogeneous inner surface and higher chemical stability. Furthermore, SCHOTT is the first manufacturer to develop a patented test method that even allows for this lower tendency to delamination to be documented – known as SCHOTT Delamination Quicktest. As a result, SCHOTT Vials DC enable pharma companies to significantly reduce and control the risk of delamination. In addition to 2R and 4R ISO formats which are already available SCHOTT will also market 6R and 8R sizes from February onwards.

With syrSCHOTT iQ® InJentle prefillable glass syringes SCHOTT provides a superior delivery system for the increasingly advanced medicines, especially sensitive biotech drugs. Biotech molecules tend to interact more easily with packaging due to their complex and sensitive makeup. With this in mind, SCHOTT designed syrSCHOTT iQ® InJentle to decrease the risk by reducing the number of materials and components the drug comes into contact with during storage. The syringe features an integrated needle system consisting of a fluid path made of a rubber bung, a needle and a tamper evident needle shield. A special ’pinch seal’ keeps the fluid path closed during storage and prevents the drug from coming into contact with the metal needle or the adhesive. In addition, thin and sharp needles allow for easy administration in a continuing effort to ensure patient safety and health.

SCHOTT is a leading international technology group in the areas of specialty glass and glass-ceramics. The company has more than 130 years of outstanding development, materials and technology expertise and offers a broad portfolio of high-quality products and intelligent solutions. SCHOTT is an innovative enabler for many industries, including the home appliance, pharmaceutical, electronics, optics, automotive and aviation industries. SCHOTT strives to play an important part of everyone’s life and is committed to innovation and sustainable success. The group maintains a global presence with production sites and sales offices in 35 countries. With its workforce of approximately 15,400 employees, sales of 1.87 billion euros were generated in fiscal year 2013/2014. The parent company, SCHOTT AG, has its headquarters in Mainz (Germany) and is solely owned by the Carl Zeiss Foundation. As a foundation company, SCHOTT assumes special responsibility for its employees, society and the environment.
Press contact
Christina Rettig
Public Relations Manager
Hattenbergstraße 10
55122 Mainz
Phone: +49 6131/66-4094
Further information
Salvatore Ruggiero
Vice President Marketing and Communication
Hattenbergstraße 10
55122 Mainz
Phone: +49 6131/66-4140